Crescent Biopharma (CBIO) vs CytomX Therapeutics (CTMX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Crescent Biopharma (CBIO) has outperformed CytomX Therapeutics (CTMX) over the past year, gaining 17.1% versus a loss of 26.7%. Over five years, CTMX leads with a -51.9% price change compared with -92.9% for CBIO. CytomX Therapeutics is the larger company by market cap ($538.2 million vs $524.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CBIO | CTMX |
|---|---|---|
| Share price | $14.12 | $2.47 |
| Market cap | $524.51M | $538.21M |
| 1-day change | +4.67% | -3.14% |
| YTD return | +19.06% | -42.02% |
| 1-year return | +17.08% | -26.71% |
| 5-year return | -92.87% | -51.95% |
| EPS (TTM) | $-7.63 | $-0.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.41 | $8.21 |
| 52-week low | $8.72 | $2.43 |
| Distance from 52-week high | -48.49% | -69.91% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +123.09% | +395.95% |
| Average volume | 399.18K | 3.38M |
| Shares outstanding | 37.14M | 217.90M |
| Employees | 69 | 69 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CBIO has outperformed CTMX by 43.8 percentage points over the past year.
About Crescent Biopharma
CBIO stock →Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About CytomX Therapeutics
CTMX stock →CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
CBIO vs CTMX FAQ
Which is bigger, Crescent Biopharma or CytomX Therapeutics?
CytomX Therapeutics (CTMX) is larger, with a market capitalization of $538.21M compared with $524.51M for Crescent Biopharma (CBIO).
Which stock has performed better over the past year, CBIO or CTMX?
CBIO returned +17.08% over the past 12 months, compared with -26.71% for CTMX (price return, excluding dividends). Past performance does not predict future results.
Are Crescent Biopharma and CytomX Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.